Perma-Fix falls nearly 9% on fourth quarter earnings, revenue miss

Perma-Fix Environmental Services (NASDAQ:PESI) stock fell nearly 9% after reporting fourth-quarter earnings and revenue that missed analyst expectations. The company reported a Q4 loss of $0.31 per share and revenue of $15.7 million, both below forecasts. Despite the miss, the company highlighted a 29% revenue increase in its treatment segment and key progress in its Perm-Fix Northwest facility permit renewal, along with increased treatment backlog and international revenue.

Original reporting
Investing.com Australia · Rachael Rajan
Published Mar 24, 2026, 11:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 24, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$PESI
Bearish
medium confidence
Mentioned
$PESI
alphai data visualization · based on Investing.com Australia
Decision brief

The 30-second read

$PESIBearishMed
01

Why it matters

The earnings miss and stock decline reflect short-term negative sentiment, but underlying operational improvements suggest potential for future growth.

02

Market read

The news is highly relevant for investors and traders holding or considering trading PESI, especially given the immediate price reaction.

03

What to watch

Potential for future earnings improvement due to increased treatment backlog and international revenue growth; macroeconomic factors could also influence stock performance.

Timing: Immediate, as the earnings report was published today.

Background

Perma-Fix reported Q4 earnings that missed analyst expectations, leading to a significant stock decline.

Company-level read

Ticker impact

$PESIBearishMedium confidence
Context

The news pertains directly to Perma-Fix Environmental Services (PESI), reporting quarterly earnings and revenue results.

Expected impact

Short-term decline of approximately 8-10%, with potential stabilization or recovery if positive operational developments continue.

Evidence & confidence

The earnings miss and stock decline indicate immediate negative sentiment. However, positive operational highlights could support a rebound, but overall uncertainty remains due to earnings disappointment.

Market effects

The earnings miss may weigh on the environmental services sector, especially companies with similar revenue structures.

Limited regional impact; effects are mostly company-specific.

Low; the news primarily affects PESI and its immediate sector.

Counterpoint

The earnings miss might be a temporary setback; positive operational developments could lead to a recovery in stock price.

Key entities

  • Perma-Fix Environmental Services

    A provider of environmental remediation services, including waste treatment and disposal.

  • Rachael Rajan

    Journalist reporting on earnings and market reactions.

Related articles

$PESIMed

Why is Perma-Fix Environmental stock slipping today?

Perma-Fix Environmental Services (PESI) fell 0.8% to $17.31 in after-hours after a Q2 2026 business update. The company pre-announced revenue of about $13M and a net loss of about $6M, citing delays in Hanford waste treatment, project starts, and higher costs. Treatment backlog rose to about $15.7M. Lock-up restrictions from a May equity offering run until mid-August.

$PESIMed

PERMA FIX ENVIRONMENTAL SERVICES INC (PESI): Results of Operations and Financial Condition

PERMA FIX ENVIRONMENTAL SERVICES INC (PESI) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0000891532 0000891532 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

$FGLMed

Founder Group Limited Secures Second Aquaculture Contract, a US$1.4 million 1.78 MW rooftop system for a Kedah shrimp Farm

Founder Group Limited (NASDAQ: FGL) said its subsidiary Founder Energy Sdn Bhd signed a turn-key EPCC contract for a 1.78 MW-peak rooftop solar system for a shrimp farming and processing facility in Ayer Hitam, Kedah. The contract is valued at about RM5.58 million (US$1.37 million). The company also cited Malaysia RE policy targets and plans for 25-year operations.

$AEHRMed

Aehr Test Systems: Aehr Receives $22 Million Follow-On Order for AI Processor Wafer-Level Burn-In Systems

Aehr Test Systems (NASDAQ:AEHR) said it received a $22 million follow-on production order from its lead wafer-level AI processor customer. The order includes multiple FOX-XP wafer-level burn-in systems plus FOX WaferPak contactors and auto aligners, testing nine 300mm wafers per system. Aehr expects shipment over six months for installation in Taiwan.

$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.